Ginkgo Bioworks Holdings Inc. Class A Common Stock Q2 2026 Earnings Recap

Shares plunged 9.3% following a steep 48% revenue decline and continued margin pressure, signaling investor disappointment with significant top-line deceleration and ongoing elevated losses despite cost-cutting efforts.

Key Takeaways

• Q2 revenue dropped 48% year-over-year to $20 million, reflecting sharp deceleration in core business.
• Adjusted EBITDA loss widened to $36 million from $25 million a year ago, indicating margin compression despite reduced operating expenses.
• Net loss from continuing operations increased to $57 million from $53 million in Q2 2025.
• Cash burn rose to $45 million in Q2, up from $38 million the prior year, despite restructuring and cost controls.
• Guidance maintained for 2026 cash burn of $125 million to $150 million, showing cautious outlook without improvement in near-term profitability.